UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis.
Cancer Chemother Pharmacol
; 79(6): 1109-1117, 2017 Jun.
Article
in En
| MEDLINE
| ID: mdl-28502040
Previous studies of irinotecan pharmacogenetics have shown that the UGT1A1*28 polymorphism has an effect on irinotecan (IRI)-induced toxicities in Caucasians. Yet compared with the UGT1A1*6 mutation, the UGT1A1*28 occurs at a much lower frequency in the Asians. Whether UGT1A1*6 and UGT1A1*28 are associated with IRI-induced neutropenia, diarrhea and IRI-based chemotherapy tumor response (TR) in Asians with lung cancer remains controversial. In this meta-analysis, we found a higher risk of neutropenia and diarrhea with IRI-based chemotherapy in Asians with lung cancer carrying the UGT1A1*6 polymorphism. However, UGT1A1*28 showed a weak correlation with diarrhea, but no significant correlation with neutropenia. Neither UGT1A1*6 nor UGT1A1*28 is associated with IRI-based chemotherapy TR. These data suggest that the UGT1A1*28 polymorphism may not be a suitable biomarker to predict IRI-induced toxicities and chemotherapy TR in Asians, while UGT1A*6 polymorphism is associated with a higher risk of IRI-induced neutropenia and diarrhea, but not IRI-based chemotherapy TR.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Camptothecin
/
Glucuronosyltransferase
/
Asian People
/
Lung Neoplasms
/
Antineoplastic Agents, Phytogenic
Type of study:
Prognostic_studies
/
Systematic_reviews
Limits:
Humans
Language:
En
Journal:
Cancer Chemother Pharmacol
Year:
2017
Document type:
Article
Country of publication:
Germany